Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men

References

• Leal J, Luengo-Fernandez R, Gray A, . Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J 2006; 27: 1610–9
   PubMed Web of Science ®Google Scholar
• Steinberg D. Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part V: the discovery of the statins and the end of the controversy. J Lipid Res 2006; 47: 1339–51
   PubMed Web of Science ®Google Scholar
• Baigent CA, Keech PM, Kearney L, . Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267–78
   PubMed Web of Science ®Google Scholar
• National Agency for Medicines and Social Insurance Institution. Finnish statistics on medicines 2006. Helsinki: Edita Prima Oy: 2007
   Google Scholar
• Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis. Br Med J 2003; 326: 1423–9
   PubMed Web of Science ®Google Scholar
• Jones PH, Davidson MH, Stein EA, . Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* trial). Am J Cardiol 2003; 92: 152–60
   PubMed Web of Science ®Google Scholar
• LaRosa JC, Grundy SM, Waters DD, . Intensive lipid lowering with atorvastatin in patients with stable coronary disease. New Engl J Med 2005; 352: 1425–35
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from randomised trial of 20 536 people. Br Med J 2006; 333: 1145–8
   PubMed Web of Science ®Google Scholar
• Davies A, Hutton J, O’Donnell J, . Cost-effectiveness of rosuvastatin, atorvastatin, simvastatin, pravastatin and fluvastatin for the primary prevention of CHD in the UK. Br J Cardiol 2006; 13: 196–202
   Google Scholar
• Huse DM, Song X, Ozminkowski RJ, . Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and medicare populations: a data analysis. Clin Ther 2006; 28: 1425–42
   PubMed Web of Science ®Google Scholar
• Johannesson M, Jönsson B, Kjekshus J, . Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian simvastatin survival study group. New Engl J Med 1997; 336: 332–6
   PubMed Web of Science ®Google Scholar
• Martikainen JA, Ottelin AM, Kiviniemi V, . Plant stanol esters are potentially cost-effective in the prevention of coronary heart disease in men: Bayesian modelling approach. Eur J Cardiovasc Prev Rehabil 2007; 14: 265–72
   PubMed Web of Science ®Google Scholar
• Bhopal R, Fischbacher C, Vartiainen E, . Predicted and observed cardiovascular disease in South Asians: application of FINRISK, Framingham and SCORE models to Newcastle heart project data. J Public Health 2005; 27: 93–100
   Web of Science ®Google Scholar
• Statistic Finland. Causes of death 2001. Publications of Statistics Finland; Helsinki: 2002
   Google Scholar
• Finnish National Public Health Institute. National cardiovascular disease register. Available at: http://ktl.fi/cvdr [Last accessed May 24, 2007]
   Google Scholar
• Häkkinen U, Idänpää-Heikkilä U, Keskimäki I, . Akuutin sydäninfarktin hoitokäytäntöjen kustannusten ja vaikuttavuuden vertailu. Aiheita 9/2002. National Research and Development Center for Welfare and Health (Stakes); Helsinki: 2002
   Google Scholar
• Lakka HM, Laaksonen DE, Lakka TA, . The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. J Am Med Assoc 2002; 288: 2709–16
   PubMed Web of Science ®Google Scholar
• Conroy RM, Pyorala K, Fitzgerald AP, . Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987–1003
   PubMed Web of Science ®Google Scholar
• Hujanen T. Terveydenhuollon Yksikkökustannukset Suomessa Vuonna 2001. Aiheita 1/2003. National Research and Development Center for Welfare and Health (Stakes); Helsinki: 2003
   Google Scholar
• Sintonen H. The 15D instrument of health-related quality of life: properties and applications. Ann Med 2001; 33: 328–36
   PubMed Web of Science ®Google Scholar
• Kattainen E, Sintonen H, Kettunen R, . Health-related quality of life of coronary artery bypass grafting and percutaneous transluminal coronary artery angioplasty patients: 1-year follow-up. Int J Technol Assess Health Care 2005; 21: 172–9
   PubMed Web of Science ®Google Scholar
• Gouveia Pinto C, Oliveira Carrageta M, Silva Miguel L. Cost-effectiveness of rosuvastatin in the prevention of ischemic heart disease in Portugal. Value Health 2008; 11: 154–9
   PubMed Web of Science ®Google Scholar
• Cooper K, Brailsford SC, Davies R, . A review of health care models for coronary heart disease interventions. Health Care Manag Sci 2006; 9: 311–24
   PubMedGoogle Scholar
• Thomsen TF, McGee D, Davidsen M, . A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup population studies and Framingham heart study. Int J Epidemiol 2002; 31: 817–22
   PubMed Web of Science ®Google Scholar
• Hense HW, Schulte H, Lowel H, . Framingham risk function overestimates risk of coronary heart disease in men and women from Germany – results from the MONICA Augsburg and the PROCAM cohorts. Eur Heart J 2003; 24: 937–45
   PubMed Web of Science ®Google Scholar
• Väistö T, Pajunen P, Jousilahti P, . Cholesterol levels of cardiovascular disease risk groups and healthy persons in the FINRISK 2002 study. Finnish Med J 2005; 60: 389–94
   Google Scholar
• Perreault S, Dragomir A, Laurier C, . Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. Br J Clin Pharmacol 2005; 59: 564–73
   PubMed Web of Science ®Google Scholar
• Peterson AM, McGhan WF. Pharmacoeconomic impact of non-compliance with statins. Pharmacoeconomics 2005; 23: 13–25
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7–22
   PubMed Web of Science ®Google Scholar
• Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions?. Health Econ 2004; 13: 437–52
   PubMed Web of Science ®Google Scholar